Journal article
Marginal zone B cells acquire dendritic cell functions by trogocytosis
P Schriek, AC Ching, NS Moily, J Moffat, L Beattie, TM Steiner, LM Hosking, JM Thurman, VM Holers, S Ishido, MH Lahoud, I Caminschi, WR Heath, JD Mintern, JA Villadangos
Science | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2022
Abstract
Marginal zone (MZ) B cells produce broad-spectrum antibodies that protect against infection early in life. In some instances, antibody production requires MZ B cells to display pathogen antigens bound to major histocompatibility complex class II (MHC II) molecules to T cells. We describe the trogocytic acquisition of these molecules from conventional dendritic cells (cDCs). Complement component 3 (C3) binds to murine and human MHC II on cDCs. MZ B cells recognize C3 with complement receptor 2 (CR2) and trogocytose the MHC II-C3 complexes, which become exposed on their cell surface. The ubiquitin ligase MARCH1 limits the number of MHC II-C3 complexes displayed on cDCs to prevent their elimina..
View full abstractRelated Projects (5)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
National Health and Medical Research Council of Australia 1058193 (J.A.V.), National Health and Medical Research Council of Australia 1016629 (W.R.H., J.A.V.), National Health and Medical Research Council of Australia 1113293 (W.R.H.), Australian Research Council DP110101383 (J.A.V.), Australian Research Council DP160103134 (J.A.V.), Human Frontier Science Program 0064/2011 (S.I., J.A.V.), National Health Institute R01 DK125823 (J.M.T., V.M.H.), NIH R01DK076690 (J.M.T.), and Australian Research Training Program Scholarship (P.S.).